Patents Represented by Attorney, Agent or Law Firm Linda O. Palladino
-
Patent number: 8318665Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: August 28, 2012Date of Patent: November 27, 2012Assignee: Stemnion, Inc.Inventors: Vivienne S Marshall, Catherine J Trumpower, Charlotte A Smith
-
Patent number: 8318197Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.Type: GrantFiled: January 17, 2012Date of Patent: November 27, 2012Assignee: Stemnion, Inc.Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel
-
Patent number: 8318672Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: April 10, 2012Date of Patent: November 27, 2012Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
-
Patent number: 8313764Abstract: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.Type: GrantFiled: June 20, 2011Date of Patent: November 20, 2012Assignee: Stemnion, Inc.Inventors: David L. Steed, Linda O. Palladino
-
Patent number: 8283316Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: April 10, 2012Date of Patent: October 9, 2012Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
-
Patent number: 8278417Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: April 10, 2012Date of Patent: October 2, 2012Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Patent number: 8221741Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: January 11, 2008Date of Patent: July 17, 2012Inventors: Vivienne S. Marshall, Richard A. Banas, Catherine J. Trumpower
-
Patent number: 8198239Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: November 15, 2011Date of Patent: June 12, 2012Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
-
Patent number: 8197804Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: May 13, 2008Date of Patent: June 12, 2012Assignee: Stemnion, Inc.Inventors: George L. Sing, Vivienne S. Marshall, Diana L. Clarke
-
Patent number: 8187881Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: December 1, 2009Date of Patent: May 29, 2012Assignee: Stemnion, Inc.Inventors: Charlotte A. Smith, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 8153423Abstract: This invention relates to the isolation and propagation of pluripotent cells isolated from the mammalian late epiblast layer, termed Epiblast Stem Cells' (EpiSCs). These cells are useful in a range of applications, including the generation of transgenic animal species.Type: GrantFiled: November 9, 2007Date of Patent: April 10, 2012Inventors: Roger Pedersen, Ludovic Vallier, Gabrielle Brons
-
Patent number: 8153430Abstract: The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.Type: GrantFiled: July 2, 2008Date of Patent: April 10, 2012Assignee: Stemnion, Inc.Inventors: Linda O. Palladino, Diana L. Clarke, Vivienne S. Marshall, Charlotte A. Smith, Martin C. Robson
-
Patent number: 8058066Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: November 30, 2009Date of Patent: November 15, 2011Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Patent number: 6660499Abstract: DCR5, a protein related to DAN (Differential-screening-selected gene Aberrative in Neuroblastoma) and related nucleic acids are provided. Included are natural DCR5 homologs from several species and proteins comprising a DCR5 domain having specific activity, particularly the ability to antagonize a bone morphogenetic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.Type: GrantFiled: February 14, 2001Date of Patent: December 9, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aris N. Economides, Neil Stahl
-
Patent number: 6645484Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: October 12, 2000Date of Patent: November 11, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, JoAnne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Patent number: 6627415Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptorbody which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention further provides for a ligandbody which specifically binds TIE-2 receptor. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth, differentiation or migration of cells expressing the TIE-2 receptor, including, but not limited to, hematopoietic precursor cells, a method of blocking the growth, differentiation or migration of cells expressing the TIE-2 receptor including, but not limited to, hematopoietic precursor cells, and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: November 18, 1999Date of Patent: September 30, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, George D. Yancopoulos
-
Patent number: 6610510Abstract: Human Cerberus proteins and related nucleic acids are provided. Included are proteins comprising a human cerberus domain having specific activity, particularly the ability to antagonize a bone morphogenic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.Type: GrantFiled: November 16, 1999Date of Patent: August 26, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David M. Valenzuela, Eduardo A. Rojas, Aris N. Economides, Neil Stahl
-
Patent number: 6602683Abstract: A novel ligand (Efl-6) that binds the Elk subfamily of Eph receptors is identified, and methods for making the soluble Elf-6 ligand in biologically active form is described. A cDNA clone encoding this novel protein enables production of the recombinant protein, which is useful to support neuronal and other eph receptor-bearing cell populations.Type: GrantFiled: April 24, 1998Date of Patent: August 5, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Nicholas W. Gale, George D. Yancopoulos
-
Patent number: 6596541Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: GrantFiled: February 16, 2001Date of Patent: July 22, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, George D. Yancopoulos
-
Patent number: 6586251Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: GrantFiled: December 7, 2000Date of Patent: July 1, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aris N. Economides, Andrew J. Murphy, David M. Valenzuela, George D. Yancopoulos